Alzheimers

Alzheimer’s Capillary Blood Biomarkers Correlated With Cognition

May 17, 2026 by BrainASAP

TL;DR: A 2026 study in Nature Communications found that self-administered finger-prick blood tests for phosphorylated tau 217 (p-tau217), an Alzheimer’s tau marker, and glial fibrillary acidic protein (GFAP), an astrocyte-injury marker, correlated with cognition and function in older adults. Key Findings Remote sampling: Participants used capillary finger-prick blood collection rather than standard clinic-based venous blood …

NDST3 Suppression Restored Lysosomal Acidification in Alzheimer’s Models

May 15, 2026 by BrainASAP

TL;DR: A 2026 study in Translational Neurodegeneration found that reducing NDST3, a microtubule deacetylase that affects lysosome acidity, restored lysosomal acidification and reduced amyloid-beta and tau pathology in Alzheimer’s cell and mouse models. Key Findings Lysosomal pH shifted back: APP695Swe-overexpressing HT22 cells had lysosomal pH near 5.6, while Ndst3 knockdown lowered it to less than …

Olfactory MRI Radiomics Linked pTau217 to Alzheimer’s Cognition

May 15, 2026 by BrainASAP

TL;DR: A 2026 article-in-press study in Alzheimer’s Research & Therapy found that olfactory-region MRI radiomics, a method that turns brain scans into quantitative texture and shape features, linked blood pTau217, a tau-related Alzheimer’s disease biomarker, with cognitive impairment across three cohorts. Key Findings Three Alzheimer’s cohorts were matched: Researchers matched 122 Alzheimer’s disease (AD) patients …

Alzheimer’s AI Model Improved Disease Progression Prediction

May 15, 2026May 15, 2026 by BrainASAP

TL;DR: A 2026 machine-learning study found that the final SNP-NF model in PLOS One reported mAUC 0.965, recall 0.929, and precision 0.929, while the study reported gains of about 3% in mAUC, 1% in precision, and 0.7% in recall versus their previous neural-process model. Key Findings SNP-NF performance was high: The final model reported mAUC …

Oral Arginine Reduced Amyloid-Beta Pathology in Two Mouse Models of Alzheimer’s Disease

May 15, 2026 by BrainASAP

TL;DR: A 2025 study in Neurochemistry International from Kindai University showed that oral arginine, a naturally occurring amino acid, blocked the formation of toxic amyloid-beta aggregates in lab tests and reduced amyloid pathology in two well-established mouse models of Alzheimer’s disease — with the authors flagging that the research-grade doses and methods are not equivalent …

Cochrane Review of 17 Trials Found Anti-Amyloid Antibodies Made No Clinically Meaningful Difference in Early Alzheimer’s

May 14, 2026 by BrainASAP

TL;DR: A 2026 systematic review in The Cochrane Database of Systematic Reviews pooled 17 trials of anti-amyloid monoclonal antibodies (N=20,342 people with mild cognitive impairment or mild Alzheimer’s dementia) and concluded that any effect on memory decline or dementia severity was either nonexistent or well below the threshold considered clinically meaningful for patients. Key Findings …

Plasma p-tau217 AI Models Lost Utility Across Cohorts

May 13, 2026May 12, 2026 by BrainASAP

TL;DR: A 2026 medRxiv preprint found that plasma p-tau217 AI models still separated amyloid-positive from amyloid-negative people across ADNI and A4, but calibration drift made the same probabilities less dependable for clinical decisions. Key Findings Calibration drift weakened clinical utility: The study trained plasma biomarker machine-learning models in one Alzheimer’s cohort and tested them in …

Plasma p-tau217 Blood Test Identified Alzheimer’s Pathology in Meta-Analysis

May 11, 2026 by BrainASAP

TL;DR: A 2026 systematic review and meta-analysis in Molecular Neurobiology found that plasma phosphorylated tau 217 (p-tau217), a blood marker of Alzheimer-linked tau pathology, identified biomarker-defined Alzheimer’s disease with pooled sensitivity of 85.4% and specificity of 88.0% across 27 studies. Key Findings 27-study evidence base: Researchers analyzed 19,652 participants from studies that compared plasma p-tau217 …

SimulAD Modeled Amyloid Clearance in Alzheimer’s Trials

May 11, 2026May 11, 2026 by BrainASAP

TL;DR: A 2026 medRxiv preprint tested SimulAD, an Alzheimer’s disease progression simulator, and reported that it reproduced mean amyloid-clearance results within 5% error across six major phase III anti-amyloid trials while also separating positive trials from null trials in retrospective power analyses. Key Findings Six phase III trials: Researchers retrospectively simulated TRAILBLAZER-ALZ2, CLARITY AD, EMERGE, …

Boosting Astrocyte Sox9 Improved Amyloid Plaque Clearance and Preserved Cognition in Alzheimer’s Mouse Models

May 15, 2026May 10, 2026 by BrainASAP

TL;DR: A 2026 study in Nature Neuroscience from Baylor College of Medicine showed that boosting Sox9, a transcription factor that regulates aging astrocytes, improved astrocytes’ ability to clear amyloid plaques in Alzheimer’s mouse models and preserved cognitive function — pointing to a treatment strategy that targets the brain’s own support cells rather than directly attacking …

+ Load more